

## Disclosures

### Personal Commercial (5)

| Company Name         | Relationship Category     | Compensation Level       | Topic Area(s)                              |
|----------------------|---------------------------|--------------------------|--|
| <i>Self</i>          |                           |                          |  |
| Abbott               | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Ancora               | Consultant Fees/Honoraria | Modest (< \$5,000)       | <i>Invasive CV Angio and Interventions</i> |
| Boston Scientific    | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Other</i>                               |
| Edwards Lifesciences | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Valvular Heart Disease</i>              |
| Medtronic            | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Valvular Heart Disease</i>              |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (10)

| Trial Name  | Trial Sponsor      | Trial Funding Source |
|-------------|--------------------|----------------------|
| PROTECT IV  | Abiomed Inc.       |                      |
| ALLAY-HF    | Alleviant          |                      |
| CORCINCH-HF | Ancora Heart, Inc. |                      |
| Agent IDE   | Boston Scientific  |                      |
| REPRISE IV  | Boston Scientific  |                      |
| SIMPLAAFY   | Boston Scientific  |                      |
| ENCIRCLE    | Edwards            |                      |
| EARLY TAVR  | Edwards            |                      |
| ALIGN AR    | JenaValve          |                      |
| Intrepid    | MEDTRONIC          |                      |

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 10/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 10/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 10/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.